Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Pathol Clin Res ; 10(4): e12389, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38970797

RESUMO

Mesonephric-type (or -like) adenocarcinomas (MAs) of the ovary are an uncommon and aggressive histotype. They appear to arise through transdifferentiation from Müllerian lesions creating diagnostic challenges. Thus, we aimed to develop a histologic and immunohistochemical (IHC) approach to optimize the identification of MA over its histologic mimics, such as ovarian endometrioid carcinoma (EC). First, we screened 1,537 ovarian epithelial neoplasms with a four-marker IHC panel of GATA3, TTF1, ER, and PR followed by a morphological review of EC to identify MA in retrospective cohorts. Interobserver reproducibility for the distinction of MA versus EC was assessed in 66 cases initially without and subsequently with IHC information (four-marker panel). Expression of PAX2, CD10, and calretinin was evaluated separately, and survival analyses were performed. We identified 23 MAs from which 22 were among 385 cases initially reported as EC (5.7%) and 1 as clear cell carcinoma. The interobserver reproducibility increased from fair to substantial (κ = 0.376-0.727) with the integration of the four-marker IHC panel. PAX2 was the single most sensitive and specific marker to distinguish MA from EC and could be used as a first-line marker together with ER/PR and GATA3/TTF1. Patients with MA had significantly increased risk of earlier death from disease (hazard ratio = 3.08; 95% CI, 1.62-5.85; p < 0.0001) compared with patients with EC, when adjusted for age, stage, and p53 status. A diagnosis of MA has prognostic implications for stage I disease, and due to the subtlety of morphological features in some tumors, a low threshold for ancillary testing is recommended.


Assuntos
Biomarcadores Tumorais , Neoplasias Ovarianas , Fator de Transcrição PAX2 , Humanos , Feminino , Neoplasias Ovarianas/patologia , Neoplasias Ovarianas/diagnóstico , Neoplasias Ovarianas/mortalidade , Fator de Transcrição PAX2/análise , Fator de Transcrição PAX2/metabolismo , Biomarcadores Tumorais/análise , Pessoa de Meia-Idade , Reprodutibilidade dos Testes , Idoso , Adulto , Estudos Retrospectivos , Prevalência , Imuno-Histoquímica , Adenocarcinoma/patologia , Adenocarcinoma/diagnóstico , Adenocarcinoma/mortalidade , Diagnóstico Diferencial , Variações Dependentes do Observador , Idoso de 80 Anos ou mais , Carcinoma Endometrioide/patologia , Carcinoma Endometrioide/diagnóstico , Carcinoma Endometrioide/mortalidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA